5-Amino-1MQ · Pep IQ

Origin & Background

Blocking the NAD+ consumer — not just adding precursors

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of NNMT — nicotinamide N-methyltransferase, an enzyme that methylates nicotinamide using S-adenosylmethionine (SAM-e) as the methyl donor. NNMT is highly expressed in adipose tissue and liver. Its activity consumes both SAM-e and nicotinamide — diverting these substrates away from NAD+ synthesis and methyl donor pathways that support epigenetic regulation.

The logical insight: rather than simply adding more NAD+ precursors (NMN or NR), what if you blocked the enzyme that wastes them? NNMT inhibition raises intracellular NAD+ by reducing nicotinamide catabolism, increases SAM-e availability (restoring methyl donor capacity for epigenetic regulation), and — critically — activates thermogenic brown-fat-like programmes in white adipocytes. This makes 5-Amino-1MQ mechanistically distinct from NMN/NR: it attacks the consumption side rather than the supply side of the NAD+ equation.

Research from the Kramer laboratory at Cornell identified 5-Amino-1MQ as a potent NNMT inhibitor in 2021, showing in obese mouse models that treatment reduced adipocyte size, activated thermogenic gene expression in fat tissue, and caused significant fat mass reduction without changes in food intake. The mechanism appeared to involve SIRT1 activation (an NAD+-dependent sirtuin) and PGC-1α upregulation — the same pathway that exercise and caloric restriction activate.

Note: 5-Amino-1MQ is included in this peptide reference because it is consistently discussed alongside peptides in the biohacking community and is commonly sourced from research peptide suppliers, despite not being a peptide itself. The mechanism — raising NAD+ and activating metabolic programmes — places it naturally alongside AICAR, NAD+/NMN, MOTS-c, and 5-Amino-1MQ in the metabolic optimisation category.

NMN/NR vs 5-Amino-1MQ: NMN and NR add nicotinamide precursors to increase NAD+ synthesis. 5-Amino-1MQ blocks NNMT, reducing NAD+ precursor catabolism. They are complementary — taking both simultaneously addresses both supply and consumption. Several community users stack all three. The combination logic is mechanistically sound; controlled trials are absent.

Science & Mechanism

NNMT inhibition — raise NAD+, activate brown fat

Mechanism of Action

NNMT inhibition: 5-Amino-1MQ binds NNMT's active site and blocks the methylation of nicotinamide to N1-methylnicotinamide. This reduces nicotinamide catabolism and increases the pool available for NAD+ synthesis via the salvage pathway — raising intracellular NAD+ particularly in adipose and liver tissue where NNMT is most active.

SAM-e restoration: NNMT consumes SAM-e (S-adenosylmethionine) as a methyl donor. Blocking NNMT increases SAM-e availability, which supports DNA methylation, histone methylation, and other epigenetic regulatory processes that decline with age and dietary deficiency.

Sirtuin activation (SIRT1, SIRT3): The increased intracellular NAD+ activates NAD+-dependent sirtuins — particularly SIRT1 and SIRT3. SIRT1 deacetylates PGC-1α, activating mitochondrial biogenesis, β-oxidation, and thermogenic programmes. This is the same pathway as caloric restriction and exercise-induced NAD+ elevation.

Brown fat activation and thermogenesis: In adipocytes, 5-Amino-1MQ treatment induces UCP1 (uncoupling protein 1) expression — the marker of brown/beige adipocyte thermogenic capacity. White adipocytes begin expressing brown fat characteristics (browning), increasing energy expenditure without changes in food intake. In obese mouse models, this produced significant reduction in fat mass.

Adipocyte size reduction: Beyond thermogenesis, NNMT inhibition reduced triglyceride accumulation in adipocytes in preclinical models — cells become smaller and more metabolically active. This may reflect a fundamental shift in adipocyte programming toward a more metabolically favourable phenotype.

Community Voices

What people report

Biohacker ReportResearch compound use — oral

"3 months of 5-Amino-1MQ 50mg daily alongside NMN 500mg. Noticeable changes: body temperature elevated slightly (thermogenic effect real), fat loss in stubborn areas without calorie deficit change, energy levels improved. No obvious side effects. The combination with NMN feels synergistic — better than either alone previously."

Female, 44. The slight body temperature elevation is consistent with UCP1-mediated thermogenesis. The community consensus on stacking with NMN/NR is strong — the complementary mechanisms (NNMT block + precursor supply) are logically sound. The fat loss in calorie-maintained protocols is the most frequently cited effect.

Metabolic ProtocolResearch compound use

"Added 5-Amino-1MQ to my existing NMN/NR protocol. 6-week check: fasting glucose down 4 points, HOMA-IR improved from 2.1 to 1.6. Nothing dramatic but directionally consistent with the metabolic claims. Combined with resistance training the body composition shift was noticeable."

Male, 52. Glucose and insulin sensitivity improvements are mechanistically expected from SIRT1 activation and improved mitochondrial function. The community is particularly interested in 5-Amino-1MQ for age-related metabolic decline where NNMT activity tends to be chronically elevated.

Safety First

Risks & what we don't know

Unknown

Off-target NNMT inhibition — NNMT is expressed in liver, kidney, and other tissues beyond adipose. Chronic inhibition in these tissues could have effects not seen in short-term adipose-focused studies. Long-term human safety is not characterised.

Unknown

Methyl donor flux effects — increasing SAM-e availability alters global methylation balance. The long-term epigenetic implications of chronically elevated SAM-e in a 5-Amino-1MQ context are unknown.

Mild

Mild GI effects — nausea and loose stools reported at higher doses (above 100mg). Generally resolves within the first week. Starting at 25–50mg and titrating up is recommended.

Honest Assessment

Editor's summary

5-Amino-1MQ represents a genuinely novel approach to the NAD+ and metabolic health space — attacking the problem from the consumption side rather than adding precursors. The animal data is compelling: fat mass reduction without calorie restriction, brown fat activation, and SIRT1/PGC-1α pathway engagement. The mechanism is well-characterised at the molecular level.

The human evidence gap is real. Community adoption is substantial and growing, but controlled human trials are essentially absent. The compound's long-term safety profile, optimal dosing, and effects in diverse metabolic contexts are not established. That said, the community experience to date is largely positive, with the fat loss and thermogenic effects being the most consistently reported outcomes.

Verdict

"A mechanistically distinct approach to the NAD+ space — blocking consumption rather than adding supply. Strong animal data for fat loss and brown fat activation. Synergistic with NMN/NR. Orally bioavailable. The fastest-growing biohacking compound of 2024–25. Human trial data is missing but growing community experience is broadly positive."